Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in Clopidogrel-Resistant ACS Patients Undergoing PCI
NCT01812330Phase 3Unknown
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (3 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Platelet Reactivity Index at 1 month. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01812330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812330.